Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Sublingual Fentanyl (EN3267) for Breakthrough Cancer Pain
NCT00262678Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Dec 2005
- Primary completion
- Dec 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breakthrough cancer pain (BTcP) comparing Fentanyl with Placebo (2 arms). Primary endpoint: Sum of Pain Intensity Difference at 30 minutes. Started Dec 2005; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT00262678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262678.